• Welcome Guest user
  • Log in | Register
 
Athens log in
Username Password  
Forgot your password?
Subscribe now to view full content , or if you already have an account,
please Login to access this feature
Subscribe now to view full content, or if you already have an account,
please Login to access this feature
Subscribe now to access this feature, or if you already have an account,
please Login.
 
 
  • Advanced search
Cambridge University Press logo
Stahl's Essential Psychopharmacology Online
In Collaboration With NEI
Stahl's Essential Psychopharmacology

Navigation

  • Home
  • Essential Psychopharmacology
  • Prescriber's Guide
  • Stahl's Illustrated
  • DrugInteraction
  • Teachers Set
 
  • My Bookmarks
  • TOC
  • Loxapine
  • Therapeutics
  • Side Effects
  • Dosing and Use
  • Special Populations
  • Art of Psychopharmacology
  • Suggested Reading

Loxapine

THERAPEUTICS

Brands

  • Loxitane
  • see index for additional brand names

Generic?

  • Yes

Class

  • Conventional antipsychotic (neuroleptic, dopamine 2 antagonist, serotonin dopamine antagonist)

Commonly Prescribed For

  • (bold for FDA approved)
  • Schizophrenia
  • Other psychotic disorders
  • Bipolar disorder

How The Drug Works

  • Blocks dopamine 2 receptors, reducing positive symptoms of psychosis
  • Although classified as a conventional antipsychotic, loxapine is a potent serotonin 2A antagonist
  • Serotonin 2A antagonist properties might be relevant at low doses, but generally are overwhelmed by high dosing

How Long Until It Works

  • Psychotic symptoms can improve within 1 week, but it may take several weeks for full effect on behavior

If It Works

  • Most often reduces positive symptoms in schizophrenia but does not eliminate them
  • Most schizophrenic patients do not have a total remission of symptoms but rather a reduction of symptoms by about a third
  • Continue treatment in schizophrenia until reaching a plateau of improvement
  • After reaching a satisfactory plateau, continue treatment for at least a year after first episode of psychosis in schizophrenia
  • For second and subsequent episodes of psychosis in schizophrenia, treatment may need to be indefinite
  • Reduces symptoms of acute psychotic mania but not proven as a mood stabilizer or as an effective maintenance treatment in bipolar disorder
  • After reducing acute psychotic symptoms in mania, switch to a mood stabilizer and/or an atypical antipsychotic for mood stabilization and maintenance

If It Doesn’t Work

  • Consider trying one of the first-line atypical antipsychotics (risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, amisulpride)
  • Consider trying another conventional antipsychotic
  • If 2 or more antipsychotic monotherapies do not work, consider clozapine

Best Augmenting Combos for Partial Response or Treatment-Resistance

  • Augmentation of conventional antipsychotics has not been systematically studied
  • Addition of a mood stabilizing anticonvulsant such as valproate, carbamazepine, or lamotrigine may be helpful in both schizophrenia and bipolar mania
  • Augmentation with lithium in bipolar mania may be helpful
  • Addition of a benzodiazepine, especially short-term for agitation

Tests

  • Since conventional antipsychotics are frequently associated with weight gain, before starting treatment, weigh all patients and determine if the patient is already overweight (BMI 25.0–29.9) or obese (BMI ≥30)
  • Before giving a drug that can cause weight gain to an overweight or obese patient, consider determining whether the patient already has pre-diabetes (fasting plasma glucose 100–125 mg/dl), diabetes (fasting plasma glucose >126 mg/dl), or dyslipidemia (increased total cholesterol, LDL cholesterol and triglycerides; decreased HDL cholesterol), and treat or refer such patients for treatment, including nutrition and weight management, physical activity counseling, smoking cessation, and medical management
  • Monitor weight and BMI during treatment
  • Consider monitoring fasting triglycerides monthly for several months in patients at high risk for metabolic complications and when initiating or switching antipsychotics
  • While giving a drug to a patient who has gained >5% of initial weight, consider evaluating for the presence of pre-diabetes, diabetes, or dyslipidemia, or consider switching to a different antipsychotic
  • Should check blood pressure in the elderly before starting and for the first few weeks of treatment
  • Monitoring elevated prolactin levels of dubious clinical benefit
 

Current Prices for Individual Subscribers (prices are subject to change)

  Pay-per-view Subscription (48 hours) Unit price

Subscribe

Stahl's Essential Psychopharmacology Online

Revised and Updated Edition 3rd Edition

ISBN: 9780511447990


$ 40
  Annual Subscription (Single User) Unit price

Subscribe

Stahl's Essential Psychopharmacology Online

Revised and Updated Edition 3rd Edition

ISBN: 9780511447983


$ 195
  Print + Online Access (One Year, Single User) Unit price

Purchase

Stahl's Essential Psychopharmacology Online

Digital Edition: Print and Online

Once you are sent the Digital Edition, just enter the code from the inside back cover to activate your one-year access to www.stahlonline.org.

ISBN: 9780521746090


$225
For pricing and information for Academic and Medical Libraries, Corporate, Nonprofit or Government Institutions and/or special sales or website sponsorship,

for the Americas please contact:
Cambridge Library Sales,
stahlonline@cambridge.org,
800-221-4512, x6535.

For the rest of the world, please contact:
academicsales@cambridge.org
or call +44 (0) 1223 325741.

Australia and New Zealand
Phone: +61 (3) 8671 1400,
Fax: +61 3 9676 9966,
Email: enquiries@cambridge.edu.au.

 

Footer links

  • About Cambridge University Press
  • About NEI
  • About Dr. Stahl
  • About the Illustrator
  • © Cambridge University Press 2008.
  • Copyright statement
  • Privacy Policy
  • Accessibility
  • Terms of use
  • FAQ
  • Help
  • View Access Details
  • Contact us